Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
December 29, 2011
Will the addition of bevacizumab to primary treatment of ovarian cancer improve progression free survival?
paclitaxel 175 mg/m2 + carboplatin AUC 6 for cycle 1
paclitaxel + carboplatin + placebo cycles 2-6
maintenance placebo cycles 7 - 22
(1) paclitaxel 175 mg/m2 + carboplatin AUC 6 cycle 1
paclitaxel + carboplatin AUC 6 + bevacizumab cycles 2-6
maintenance placebo cycles 7 - 22
(2) paclitaxel 175 mg/m2 + carboplatin AUC 6 cycle 1
paclitaxel + carboplatin + bevacizumab cycles 2-6
maintenance bevacizumab cycles 7 - 22
Originally OS, but was changed to PFS during the study
Epithelial ovarian carcinoma
Stage III with any residual and Stage IV
Borderline ovarian tumors
Recurrent cancers
Prior radiation
(1) vs (2) vs Control:
median f/u: 17.2 mos
Median PFS: 11.2 vs 14.1 vs 10.3 mos (SS)
Median OS: 38.7 vs 39.7 vs 39.3 mos (NS)
Hypertension: 16.5% vs 22.9% vs 7.2% (SS)
GI perforation/fistula: 2.8% vs 2.6% vs 1.2%
Chemotherapy plus bevacizumab followed by bevacizumab maintenance improved PFS by 4 mos in advanced stage ovarian cancer after surgical resection.